KRAS and neoplasm: Recently, Coelho et al. unveiled a novel function of oncogenic KRAS signaling (mainly the KRASG12V mutation) in driving tumor cell PD-L1 expression, thereby impairing adaptive immune surveillance and favoring tumor growth (12).